Sarepta Therapeutics (SRPT) Set to Release Quarterly Earnings on Thursday

Sarepta Therapeutics (NASDAQ:SRPT) will likely be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Sarepta Therapeutics to announce earnings of $0.0740 per share and revenue of $352.20 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. During the same quarter in the prior year, the business earned $2.02 EPS. The company’s revenue for the quarter was down 34.3% compared to the same quarter last year. On average, analysts expect Sarepta Therapeutics to post $3.27 EPS for the current fiscal year and $1.34 EPS for the next fiscal year.

Sarepta Therapeutics Stock Down 1.6%

SRPT stock opened at $18.32 on Tuesday. The company has a 50 day moving average of $19.23 and a two-hundred day moving average of $18.71. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -6.32, a PEG ratio of 0.35 and a beta of 0.38. Sarepta Therapeutics has a 12-month low of $14.68 and a 12-month high of $24.68. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Needham & Company LLC reiterated an “underperform” rating on shares of Sarepta Therapeutics in a report on Monday, September 28th. JPMorgan Chase & Co. lowered their target price on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, September 30th. William Blair raised Sarepta Therapeutics to a “hold” rating in a research report on Wednesday, September 23rd. Benchmark reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday, September 9th. Finally, Zacks Research downgraded Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and seven have given a Sell rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Hold” and an average price target of $22.88.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.